CriticalProkinetic, peripheral dopamine D2 receptor antagonist×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
Ritonavir is a strong inhibitor of CYP3A and CYP2D6, with a greater effect on CYP3A4, and can raise the plasma levels of drugs mainly metabolised by CYP3A (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and in vitro data suggest that drugs that markedly inhibit this enzyme may raise domperidone plasma levels (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (AEMPS). In healthy volunteers, ritonavir 400 mg twice daily prolonged the Fridericia-corrected QT interval by a maximum mean of 5.5 ms compared with placebo and moderately prolonged the PR interval (EMA). The documents do not say how much ritonavir raises domperidone levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ritonavir causes a moderate, asymptomatic PR prolongation in some healthy people. Second- or third-degree atrioventricular block has been reported rarely in people with structural heart disease or conduction system abnormalities, or in those taking drugs that prolong the PR interval (ritonavir SmPC, European Medicines Agency, EMA). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with strong CYP3A4 inhibitors regardless of their own effect on the QT interval and names protease inhibitors, including ritonavir, among them (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraindication sets no dose condition, so it also covers the low doses at which ritonavir is mostly used to boost other protease inhibitors (AEMPS; ritonavir SmPC, European Medicines Agency, EMA). When ritonavir boosts another protease inhibitor, check the contraindications in the SmPC of that drug as well (EMA). Domperidone, for example, is contraindicated with darunavir boosted with ritonavir or cobicistat (darunavir SmPC, EMA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). If domperidone and ritonavir have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5